Successful treatment of refractory generalized myasthenia gravis with rituximab

European Journal of Neurology

Volumn 16, Issue 2, 2009, Pages 246-250

  Lebrun, C ^a,b   Bourg, V ^b   Tieulie, N ^b   Thomas, P ^b  

^a PASTEUR HOSPITAL   (France)

^b Universitary Hospital   (France)

Author keywords

Anti MuSK antibodies; Myasthenia; Rituximab

Indexed keywords

CD20 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; MALE; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MYASTHENIA GRAVIS;

EID: 58349108549     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02399.x     Document Type: Article

References (20)

1. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003 61 : 1438 1440.
2. Burns T, Wolfe G, Nations S, Trivedi J, Phillips LT et al. Variable MuSK antibody positive rates among seronegative MG in the United States. Neurology 2008 70 Suppl. 1 A301.
3. Hoch W, McConville J, Helms S, Newson-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine 2001 7 : 365 368.
4. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003 126 : 2304 2311.
5. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Annals of Oncology 2003 14 : 520 535.
6. Goldfarb AR, Weimer LH, Brannagan TH III. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle and Nerve 2005 31 : 510 515.
7. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and auto-immune diseases. Annual Review of Medicine 2004 55 : 477 503.
8. Silverman GJ, Weisman S. Rituximab therapy and auto-immune disorders: prospects for anti-B cell therapy. Arthritis Rheumatid 2003 48 : 1484 1492.
9. Zaja FF, Russo DD, De Vita SS, et al. Rituximab for the treatment of auto-immune diseases. Blood 2001 98 : 41b.
10. Scuderi F, Marino M, Colonna L, et al. Anet-p110 autoantibodies identify a subtype of seronegative myasthenia gravis with prominent oculobulbar involvement. Laboratory Investigation 2002 82 : 1139 1146.
11. Sanders DB, El-Salem K, Massey JM, McConville J, Vinecnt A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003 60 : 1978 1980.
12. Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in patient with non-Hodgkin lymphoma. American Journal of Hematology 2004 77 : 196 197.
13. Baek WS, Bashey A, Sheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 2007 78 : 771.
14. Hain BH, Jordan K, Deschauer M, zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle and Nerve 2006 33 : 575 580.
15. Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. Journal of Pediatrics 2003 143 : 674 677.
16. Takagi K, Yoshida A, Iwasaki H, Inoue H, Ueda T. Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma. Annals of Hematology 2005 84 : 5458 5550.
17. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. Journal of Neurology 2007 254 : 968 969.
18. Illa I, Diaz-Manera J, Rojas-Garcia R et al. Rituximab in refractory myasthenia gravis: a follow-up study of patients with anti-AchR or anti-Musk antibodies. Neurology 2008 70 Suppl. 1 A301.
19. Rup T, Potter C, Bradshaw Y. Pilot trial of rituximab in myasthenia gravis. Neurology 2008 70 Suppl. 1 A301.
20. Gardner R, Pestronk A, Al-Lozi M. Intractable myasthenia gravis responding to rituximab treatment. Neurology 2008 70 Suppl. 1 A301.